143 related articles for article (PubMed ID: 35459549)
21. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
23. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
Vandenput I; Van Calster B; Capoen A; Leunen K; Berteloot P; Neven P; Moerman P; Vergote I; Amant F
Br J Cancer; 2009 Jul; 101(2):244-9. PubMed ID: 19568245
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
26. Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
Huang K; Jakub J; Gabriel E; Moreno-Aspitia A; McLaughlin S
Ann Surg Oncol; 2023 Nov; 30(12):7026-7035. PubMed ID: 37490162
[TBL] [Abstract][Full Text] [Related]
27. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
28. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
Wright JD; Huang Y; Melamed A; Albright BB; Hillyer GC; Previs R; Hershman MSDL
Gynecol Oncol; 2021 Sep; 162(3):599-605. PubMed ID: 34158181
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.
de Lange NM; Ezendam NPM; Kwon JS; Vandenput I; Mirchandani D; Amant F; van der Putten LJM; Pijnenborg JMA
Curr Oncol; 2019 Apr; 26(2):e226-e232. PubMed ID: 31043831
[TBL] [Abstract][Full Text] [Related]
30. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
31. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.
Bristow RE; Zerbe MJ; Rosenshein NB; Grumbine FC; Montz FJ
Gynecol Oncol; 2000 Aug; 78(2):85-91. PubMed ID: 10926785
[TBL] [Abstract][Full Text] [Related]
32. Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
Zhou ZN; Chen L; Melamed A; St Clair CM; Hou JY; Khoury-Collado F; Gockley A; Hershman DL; Wright JD
Gynecol Oncol; 2022 Feb; 164(2):341-347. PubMed ID: 34920885
[TBL] [Abstract][Full Text] [Related]
33. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Liu YL; Filippova OT; Zhou Q; Iasonos A; Chi DS; Zivanovic O; Sonoda Y; Gardner GJ; Broach VA; O'Cearbhaill RE; Konner JA; Aghajanian C; Long Roche K; Tew WP
J Gynecol Oncol; 2020 Jan; 31(1):e17. PubMed ID: 31833259
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
36. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Bogani G; Matteucci L; Tamberi S; Arcangeli V; Ditto A; Maltese G; Signorelli M; Martinelli F; Chiappa V; Leone Roberti Maggiore U; Perotto S; Scaffa C; Comerci G; Stefanetti M; Raspagliesi F; Lorusso D
Int J Gynecol Cancer; 2017 Nov; 27(9):1856-1862. PubMed ID: 29064913
[TBL] [Abstract][Full Text] [Related]
38. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
[TBL] [Abstract][Full Text] [Related]
39. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
40. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
